TB Alliance Congratulates MSF on TB-PRACTECAL Milestone

Written By Jess Wiggs

PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study.

TB-PRACTECAL is a Phase 2/3 clinical trial sponsored by Médecins Sans Frontières/ Doctors Without Borders (MSF) that is evaluating bedaquiline/pretomanid/linezolid (BPaL) based regimens for the treatment of multidrug-resistant tuberculosis.

TB Alliance is proud to partner with MSF in pursuit of our shared goal of finding short, simple, safe and effective regimens for this deadly disease. We look forward to the presentation and publication of the data from this study.

Jess Wiggs
Previous

STAND Clinical Trial Results Published
Next

Amid Global Pandemic, TB Treatment Innovation Advances at an Unprecedented Pace